Company / Free Cash Flow
Nurix Therapeutics, Inc. Free Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$263.5M
FY2025
5-year range
-$263.5M / -$1.1M
FY2021-FY2025
Trend
-44.9%
vs FY2024
Sector context
#162 of 194
Health Care
What the data says
Nurix Therapeutics, Inc.'s free cash flow of -$263M is lower than 84% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 7 years, ranging from -$263M in FY2025 to -$1M in FY2021.
Based on SEC 10-K filings.
-$263M in FY2025.
Declined from -$90M to -$263M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 194This company -$263.5M Sector average $470.8M
▼
-156.0% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 44.9% year-over-year.
- Ranks #162 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$263.5M | -44.9% |
| FY2024 | -$181.9M | -102.6% |
| FY2023 | -$89.8M | +0.3% |
| FY2022 | -$90.0M | -8473.9% |
| FY2021 | -$1.1M | +77.3% |
| FY2020 | -$4.6M | -341.2% |
| FY2019 | -$1.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026